FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a method of producing a highly purified, functionally active protein NSP1 SARS-CoV-2 and a method for testing the activity of the highly purified protein NSP1 SARS-CoV-2, obtained using the method described above, for inhibiting translation in an RRL translation system in vitro. Method of producing NSP1 SARS-CoV-2 protein involves creating an expression construct pET-6xHIS-SUMO-NSP1 using a set of primers with sequences SEQ ID NO: 1–4 and recovery of recombinant protein NSP1 SARS-CoV-2 during two rounds of metal-chelate affinity chromatography.
EFFECT: invention extends the range of methods for producing purified functionally active protein NSP1 SARS-CoV-2.
2 cl, 6 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
| VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743595C1 |
| PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
| PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
| METHOD OF OBTAINING RECOMBINANT ANTIGEN MBP_RBD_6HIS OF SARS-CoV-2 VIRUS WITH C-TERMINAL AFFINITY TAG 6XHIS-TAG, INTENDED FOR USE AS COMPONENT OF REAGENT KIT FOR COVID-19 SERODIAGNOSTICS | 2023 |
|
RU2813324C1 |
| AGENT FOR INHIBITION OF REPLICATION OF SARS-COV-2 VIRUS MEDIATED BY RNA INTERFERENCE | 2020 |
|
RU2733361C1 |
| RECOMBINANT SARS-CoV-2 S PROTEIN RBD-BINDING PROTEIN | 2022 |
|
RU2778942C1 |
| REGULATORY SEQUENCE TO INCREASE GENE EXPRESSION | 2022 |
|
RU2804421C1 |
| RECOMBINANT DNA ENSURING PRODUCTION OF THE RECOMBINANT PROTEIN COV1 EXHIBITING IMMUNOGENIC PROPERTIES AGAINST SARS-COV-2 VIRUS | 2021 |
|
RU2776484C1 |
| IMMUNOLIPOSOME WHICH BINDS TO RBD OF S-PROTEIN SARS-CoV-2 | 2023 |
|
RU2827165C1 |
